Skip to content

Lakefront Biotherapeutics

US · LKFT #2803 by market cap Listed 1970
33.31 -0.08 -0.24%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:26

Price chart

Pre-market 33.57 +0.54%
After-hours 33.31 0.00%
Overnight 33.53 +0.42%
34.7926.0833.312026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on LKFT?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +14.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 2.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A+

The radar needs all six factors. Available grades are shown below.

Valuation A-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 2.5x Better than 99%
Price / Sales 2.2x Better than 54%
P/E vs own 5-yr range 61st pctl Better than 48%
Growth A+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 66.4% Better than 97%
Net income CAGR (3Y) 40.5% Better than 85%
Free cash flow CAGR (3Y) 138.0% Better than 96%
Profitability A

How much profit the business keeps from each dollar of sales and capital.

Gross margin 97.3% Better than 99%
Operating margin 45.1% Better than 97%
Net margin 28.8% Better than 89%
Return on equity 10.5% Better than 54%
Return on invested capital 9.4% Better than 66%
Momentum A

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 15.7% Better than 95%
6-month return 21.2% Better than 84%
12-month return (ex latest month) 3.2% Better than 38%
Distance below 52-week high 8.1% Better than 88%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 20.1x Better than 98%
Debt to assets 0.2% Better than 97%
Interest coverage 136.7x Better than 94%
Free cash flow / net income 2,110.8% Better than 98%
Analyst View N/A

What the Street thinks: share of Buy ratings and upside to the average target.

Not enough data to grade this factor.

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -1.97%
1M +8.33%
3M +17.83%
6M +21.57%
YTD +1.87%
1Y +10.15%
3Y -10.91%
5Y -35.27%

Key statistics

Price & volume

Prev close
33.39
Open
33.61
Day range
33.25 - 33.85
Avg price
33.43
Volume
162.49K
Turnover
5.43M
Amplitude
1.80%
52-week range
25.68 - 36.24

Valuation

P/E
6.24
P/E (TTM)
2.51
P/B
0.62
EPS
5.34
Net profit
349.75M
Net assets
3.55B

Share structure

Market cap
2.18B
Float cap
796.48M
Shares out
65.48M
Float shares
23.91M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 72% of range
25.68 36.24

8.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-974.37K net over the window

Short interest

Shares short
1.30M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Lakefront Biotherapeutics (LKFT)?

Lakefront Biotherapeutics last traded at 33.31. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Lakefront Biotherapeutics's market cap?

About 2.18B.

What is the P/E ratio of Lakefront Biotherapeutics?

The trailing twelve-month P/E is 2.51, below its own 5-year average of 15.34 — in the middle of its historical range (60.80% percentile). See the Valuation tab for the full history.

Does Lakefront Biotherapeutics pay a dividend?

Lakefront Biotherapeutics does not currently pay a regular dividend.

Is Lakefront Biotherapeutics a buy according to analysts?

The consensus of 2 analysts is a Buy rating, with an average 12-month price target of 45.00, which implies 35.1% upside from the current price. This is not investment advice.

What is Lakefront Biotherapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Lakefront Biotherapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 16:26:21 · For reference only, not investment advice and not tailored to your situation.

Lakefront Biotherapeutics discussion 0 comments

Add a comment